Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD-crossover comparative study with famotidine and low-dose lansoprazole

Digestive and Liver Disease

Volumn 37, Issue 7, 2005, Pages 485-490

  Adachi, K ^a   Hashimoto, T ^b   Komazawa, Y ^a   Mihara, T ^a   Furuta, K ^a   Fujishiro, H ^a   Ishihara, S ^a   Amano, Y ^a   Hattori, S ^b   Kinoshita, Y ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b Unnan General Hospital   (Japan)

Author keywords

Gastro oesophageal reflux disease; H. pylori; H2 receptor antagonist; Proton pump inhibitor

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; STOMACH SECRETION INHIBITOR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; OMEPRAZOLE; PROTON PUMP;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; MALE; MULTICENTER STUDY; REMISSION; SERODIAGNOSIS; STOMACH ACID SECRETION; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; COMORBIDITY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG TOLERANCE; MICROBIOLOGY; MIDDLE AGED; PAIN ASSESSMENT; PROSPECTIVE STUDY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; COMORBIDITY; CROSS-OVER STUDIES; DRUG TOLERANCE; FAMOTIDINE; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MIDDLE AGED; OMEPRAZOLE; PAIN MEASUREMENT; PROSPECTIVE STUDIES; PROTON PUMPS;

EID: 26944494976     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.12.016     Document Type: Article

References (26)

1. Ghillebert G., Demeyere A.M., Janssens J., and Vantrappen G. How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease?. Dig Dis Sci 40 (1995) 1317-1324
2. Mittal R.K., Holloway R.H., Penagini R., Blackshaw L.A., and Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 109 (1995) 601-610
3. Bell N.J.V., and Hunt R.H. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33 (1992) 118-124
4. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17 (1997) 22-37
5. Jansen J.B., and Van Oene J.C. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 13 (1999) 1611-1620
6. Kawano S., Murata H., Tsuji S., Kubo M., Tatsuta M., Iishi H., et al. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol 17 (2002) 955-959
7. Hurlimann S., Abbuhl B., Inauen W., and Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 8 (1994) 193-201
8. Netzer P., Gaia C., Sandoz M., Huluk T., Gut A., Halter F., et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 94 (1999) 351-357
9. Lachman L., and Howden C.W. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 95 (2000) 57-61
10. Komazawa Y., Adachi K., Mihara T., Ono M., Kawamura A., Fujishiro H., et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subject without Helicobacter pylori infection. J Gastroenterol Hepatol 18 (2003) 678-682
11. Calam J., Gibbons A., Healey Z.V., Bliss P., and Arebi N. Review article: How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 113 Suppl. 6 (1997) S43-S49
12. Fujisawa T., Adachi K., Komazawa Y., Mihara T., Azumi T., Katsube T., et al. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. Aliment Pharmacol Ther 20 (2004) 559-565
13. Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45 (1999) 172-180
14. Adachi K., Kawamura A., Ono M., Masuzaki K., Takashima T., Yuki M., et al. Comparative evaluation of urine-based and other minimally invasive methods for the diagnosis of Helicobacter pylori infection. J Gastroenterol 37 (2002) 703-708
15. Takashima T., Adachi K., Kawamura A., Yuki M., Fujishiro H., Rumi M.A.K., et al. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter 7 (2002) 86-90
16. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 28 Suppl. 199 (1993) 18-21
17. Dimenas E., Carlsson G., Glise H., Israelsson B., and Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 31 Suppl. 221 (1996) 8-13
18. Enck P., Dubois D., and Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 34 Suppl. 231 (1999) 48-54
19. Farup C., Kleinman L., Sloan S., Ganoczy D., Chee E., Lee C., et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 161 (2001) 45-52
20. Blum R.A., Shi H., Karol M.D., Greski-Rose P.A., and Hunt R.H. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 19 (1997) 1013-1023
21. van Herwaarden M.A., Samsom M., van Nispen C.H., Mulder P.G., and Smout A.J. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 13 (1999) 731-740
22. Adachi K., Fujishiro H., Katsube T., Yuki M., Ono M., Kawamura A., et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16 (2001) 1191-1196
23. Tefera S., Hatlebakk J.G., and Berstad A. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease. Am J Gastroenterol 96 (2001) 969-974
24. Peghini P.L., Katz P.O., Bracy N.A., and Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93 (1998) 763-767
25. Katsube T., Adachi K., Kawamura A., Amano K., Uchida Y., Watanabe M., et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14 (2000) 1049-1056
26. Stanghellini V., Cogliandro R., Cogliandro L., De Giorgio R., Barbara G., and Corinaldesi R. Unsolved problems in the management of patients with gastro-oesophageal reflux disease. Dig Liver Dis 35 (2003) 843-848